PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (NZ319906) Method and pharmaceutical composition for regulating lipid concentration

Office : New Zealand
Application Number: 319906 Application Date: 02.10.1996
Publication Number: 319906 Publication Date: 28.02.2000
Grant Number: Grant Date: 13.07.2000
Publication Kind : B
Prior PCT appl.: Application Number:PCTUS1996015854 ; Publication Number: Click to see the data
IPC:
A61K 31/40
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
CPC:
A61K 31/40
A61K 31/165
A61K 31/17
A61K 31/215
A61K 31/22
A61K 31/255
A61K 31/325
A61K 31/365
A61K 31/405
A61K 31/41
A61K 31/44
A61K 45/06
Y02A 50/406
Y10S 514/824
Applicants: WARNER-LAMBERT COMPANY
Inventors: Bocan, Thomas M A
Agents: BALDWINS INTELLECTUAL PROPERTY
Priority Data: 95 6155 02.11.1995 US
Title: (EN) Method and pharmaceutical composition for regulating lipid concentration
Abstract:
(EN) Patent 319906 The application is for a combination of an ACAT inhibitor, (for example, sulfamic acid, [[2,4,6,-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester), and an HMG-CoA-reductase inhibitor, (for example, atorvastatin), effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
Also published as:
CZPV1998-1271IS4720NO19981961SK55798KR1020040029459SG53241
IL123902EP0858336US6124309JPH11515025 CN1201389CN1679953
CA2233558EA199800420KR1019990067270NZ512484AU1996072539IN2115/DEL/1996
GEP20001898BWO/1997/016184